175136-45-5

Basic information

• Product Name: 4-PENTYLBENZALDEHYDE OXIME
• Synonyms: 4-PENTYLBENZALDEHYDE OXIME;4-N-PENTYLBENZALDEHYDE OXIME
• CAS NO: 175136-45-5
• Molecular Formula: C12H17NO
• Molecular Weight: 191.27
• Mol File: 175136-45-5.mol

Chemical Properties

• Boiling Point: 285.564 °C at 760 mmHg
• Flash Point: 169.125 °C
• Appearance: /
• Density: 0.964 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.507
• PKA: 10.81±0.10(Predicted)
• CAS DataBase Reference: 4-PENTYLBENZALDEHYDE OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PENTYLBENZALDEHYDE OXIME(175136-45-5)
• EPA Substance Registry System: 4-PENTYLBENZALDEHYDE OXIME(175136-45-5)

Safety Data

• Hazardous Substances Data: 175136-45-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-PENTYLBENZALDEHYDE OXIME is used as an intermediate in the synthesis of various pharmaceutical compounds.
Used in Perfume Industry:
4-PENTYLBENZALDEHYDE OXIME is used as a raw material in the production of perfumes.
Used in Dye Industry:
4-PENTYLBENZALDEHYDE OXIME is used as a precursor in the manufacturing of dyes.
Used in Food Industry:
4-PENTYLBENZALDEHYDE OXIME is used as a preservative due to its antioxidant and radical scavenging properties.
Used in Synthesis of Heterocyclic Compounds:
4-PENTYLBENZALDEHYDE OXIME is used as a starting material in the synthesis of heterocyclic compounds.
Used in Antimicrobial and Antifungal Applications:
4-PENTYLBENZALDEHYDE OXIME is used as an antimicrobial and antifungal agent due to its properties.

InChI:InChI=1/C12H17NO/c1-2-3-4-5-11-6-8-12(9-7-11)10-13-14/h6-10,14H,2-5H2,1H3/b13-10+

Upstream product

• 51554-95-1 4-pentylbromobenzene 
• 6853-57-2 4-pentylbenzaldehyde 

Relevant articles and documents

Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus

Antibiotic resistance among clinically significant bacterial pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. As a part of continuing effort to develop antibacterial agents, we rationally designed and synthesized two series of 4,5-dihydroisoxazol-5-yl and 4,5-dihydroisoxazol-3-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compound A16 possessing the 4,5-dihydroisoxazol-5-yl group showed outstanding antibacterial activity (MIC, ≤0.125–0.5 μg/mL) against various testing strains, including methicillin-resistant, penicillin-resistant and clinical isolated S. aureus strains. Besides, further mouse infection model revealed that A16 could be effective in vivo and non-toxic to Hela cells. Finally, a detailed discussion of structure-activity relationships was conducted, referring to the docking results. It is worth noting that substituting a 4,5-dihydroisoxazole ring for the isoxazole ring not only broadened the antibacterial spectrum but also resulted in a significant increase in antibacterial activity against S. aureus strains. Taken together, these results suggest a promising chemotype for the development of new FtsZ-targeting bactericidal agents.

Azole-based non-peptidomimetic plasmepsin inhibitors

The spread of drug-resistant malaria parasites urges the search for new antimalarial drugs. Malarial aspartic proteases – plasmepsins (Plms) – are differentially expressed in multiple stages of the Plasmodium parasite's lifecycle and are considered as attractive drug targets. We report the development of novel azole-based non-peptidomimetic plasmepsin inhibitors that have been designed by bioisosteric substitution of the amide moiety in the Actelion amino-piperazine inhibitors. The best triazole-based inhibitors show submicromolar potency toward Plm II, which is comparable to that of the parent Actelion compounds. The new inhibitors can be used as a starting point for the development of a resistance-free antimalarial drug targeting the non-digestive Plm IX or X, which are essential for the malaria parasite life cycle.

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Antibiotic resistance among clinically significant bacterial pathogens is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compounds B14 and B16 that possessed the isoxazol-5-yl group showed strong antibacterial activity against various testing strains, including methicillin-resistant Staphylococcus aureus and penicillin-resistant S. aureus. Further molecular biological studies and docking analyses proved that the compound functioned as an effective inhibitor to alter the dynamics of FtsZ self-polymerization via a stimulatory mechanism, which finally terminated the cell division and caused cell death. Taken together, these results could suggest a promising chemotype for development of new FtsZ-targeting bactericidal agent.

SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS

The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.